RANIBIZUMAB
Information current as at: 1 July 2026
PBAC meeting date: November 2026
Submission Details
- Brand name:
-
- Solentis®
- Simulara®
- Form and strength:
-
- Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe
- Solution for intravitreal injection 2.3 mg in 0.23 mL
- Submission sponsor:
- GENERIC HEALTH PTY LTD
- Condition/indication:
(therapeutic use) -
- Branch retinal vein occlusion with macular oedema Central retinal vein occlusion with macular oedema Proliferative diabetic retinopathy and/or diabetic macular oedema Subfoveal choroidal neovascularisation
- Listing requested:
- To request listing of two new ranibizumab biosimilars that mirror the originator brand's current listings.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required for initial treatment Authority Required (STREAMLINED) for continuing treatment
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
2Opportunity for consumer comment:
- Open 22/07/2026 and close 16/09/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1302
Page last updated
23 July 2026
v.9.19